The dinner-table co-founder who learned biology from Nobel laureates and taught Washington how to fight a pandemic.
Physician-scientist. Venture founder. The man who assembles Nobel-level scientists and turns their ideas into companies before anyone else knows they exist.
He doesn't wait for a startup to pitch him. He has dinner with a scientist, finds the idea neither of them can stop thinking about, and starts building a company around it before the paper is published.
Thomas J. Cahill, MD, PhD runs Newpath Partners from a Prudential Center office in Boston's Back Bay - but the real work happens over dinner tables, in Cambridge labs, and in the kind of late-night conversations that end with a whiteboard full of molecular diagrams and a handshake on a new company.
Cahill is the rare venture capitalist who reads the actual papers. He studied under Roald Hoffmann (Nobel Prize, Chemistry) at Cornell. Then under Richard Zare at Stanford. Then his PhD at Duke under Robert Lefkowitz - the Nobel laureate who cracked the mystery of G-protein coupled receptor signaling, the molecular switches behind nearly a third of all FDA-approved drugs. Cahill's thesis work on cellular receptors led him to found Molindra Therapeutics around his own scientific discovery before he ever wrote a term sheet.
The career pivot came through a friend's connection to the Raptor Group, where he managed life science and healthcare investments. He left to found Newpath Partners in 2018 with about $125 million in initial capital and a thesis that most VCs would consider backwards: don't fund existing startups - build companies from scratch with the scientists who made the discoveries. Portfolio companies have since raised more than $4 billion.
"Scientists want to work with people who understand science. It isn't academics coming to me with companies - we are building companies based on ideas we are discussing over dinner."Tom Cahill — Boston Globe, 2021
Most people who end up running a $350 million biotech fund went to MIT or Caltech. Tom Cahill graduated from Hobart and William Smith Colleges in 2009 with a chemistry degree - a liberal arts institution of about 2,000 students perched on the edge of Seneca Lake in upstate New York. It was there, through connections to Cornell's chemistry department, that he ended up doing undergraduate research with Roald Hoffmann, who had won the Nobel Prize in Chemistry in 1981 for his work on chemical reactions. That's where the academic trajectory started to become clear.
From Geneva, New York, he went to Stanford for a master's in chemistry, where he studied reaction dynamics under Professor Richard Zare - one of the most cited physical chemists in the world. Then came Duke, where he did the work that would define his scientific identity: a PhD in structural biology focused on rare genetic diseases, under Robert Lefkowitz.
Lefkowitz had won the Nobel Prize in Chemistry in 2012 - the year before Cahill started his doctoral work - for discovering how G-protein coupled receptors work. These receptors are embedded in cell membranes and act as molecular on/off switches. About 800 of them exist in the human genome. About one-third of all FDA-approved drugs work by targeting them. Cahill's thesis was about understanding how they behave at the structural level, and how that understanding could point toward novel drug development. He published peer-reviewed research and won academic awards. He also started thinking about what would happen if you took that science out of the lab.
Cahill has said he determined he could have greater impact by identifying promising scientists and helping them solve scientific and financial challenges - rather than conducting research himself. The transition came through a friend, who got him in front of the Raptor Group - a Boston-based investment firm with tentacles across tech, media, and life sciences. He joined Raptor to help build out their life science and healthcare portfolio.
But Raptor was investing in existing companies. Cahill had a different thesis forming: what if you started earlier? What if the venture fund was the co-founder?
Newpath Partners launched in 2018 with roughly $125 million. From the beginning, the model was unusual. Cahill wasn't backing startups that came to pitch him. He was partnering with academic scientists at the earliest possible stage - sometimes before a company existed at all - and helping them build it from the ground up. The scientific founders kept meaningful equity stakes. Management teams were brought in to complement, not override, the scientists. Cahill or a Newpath partner took a board seat at nearly every company.
The scientists Newpath partnered with in Fund II read like a Nobel Prize shortlist. David Liu of the Broad Institute - inventor of base editing and prime editing, two of the most significant CRISPR advances of the past decade. Ben Cravatt of the Scripps Research Institute - a pioneer in chemical biology. Keith Joung of Massachusetts General Hospital, a gene editing leader. Stuart Schreiber, a co-founder of the Broad Institute. Ron Vale of Janelia Research Campus. These are not names you find in a generic VC deck.
By the time Fund II closed at $350 million in late 2021, Newpath had co-founded more than a dozen companies. Prime Medicine - the David Liu gene editing company - went public on Nasdaq in 2022 under the ticker PRME. Portfolio companies in total had raised more than $4 billion.
In March 2020, as the COVID-19 pandemic closed borders and shut down normal life, Cahill noticed something: science and medicine were the furthest things removed from everything happening in Washington. The government was drowning in noise. The best research was buried. He assembled a coalition called Scientists to Stop COVID-19 - a non-partisan group of leading researchers and billionaires, functioning as a remote review board, evaluating coronavirus research and filtering the signal from the noise for policymakers.
The coalition wrote a 17-page report with specific recommendations on vaccine and therapeutic production. Several of those recommendations were adopted by the FDA. Cahill also leveraged his network - which extended to Vice President Mike Pence's aide Nick Ayers - to help get FDA approval expedited for Regeneron to shift manufacturing to Dublin. Nobel laureate Michael Rosbash said of the moment: that Cahill's successful advocacy was "proof positive that what we were doing was starting to work."
He was 33 years old, running a fund of $125 million, with zero political experience. He did it anyway.
In January 2024, Cahill co-founded Arena BioWorks alongside Stuart Schreiber, investor Steve Pagliuca of the Boston Celtics ownership group, and a scientific team including Keith Joung. Arena launched with $500 million in backing and was described as a "privately funded, fully independent biomedical institute" - a for-profit Broad Institute analogue designed to accelerate the translation of academic discoveries to the clinic.
Arena shut down in November 2025, a victim of the broader biotech funding slump that began in 2022 and the challenges of an unorthodox institutional model. About 50 staff members were let go. For Cahill, it was a real experiment that didn't survive the market cycle - not a scandal, not a failure of science, just a venture that ran into unfavorable conditions. The core question Arena was trying to answer - how do you get the best scientists in the world to work together, and faster? - remains open.
Newpath Partners continues. The most recent investments span weight-loss biology (Metsera, $215M Series B in late 2024), chromatin research (nChroma Bio, Series A in December 2024), and cancer immunology. The dinner-table thesis keeps producing companies.
When COVID-19 hit, the 33-year-old founder of a $125M venture fund did something no one asked him to do: he assembled the most connected group of scientists and billionaires in America and turned them into a real-time advisory body for the federal government. The group was called Scientists to Stop COVID-19. It operated like a covert Manhattan Project - reading every preprint, filtering out the junk, and sending curated intelligence to policymakers who were drowning in bad information.
Cahill's scientific network gave the group credibility. His political network gave them access. Together, those two things gave them influence.
Scientists want to work with people who understand science. It isn't academics coming to me with companies - we are building companies based on ideas we are discussing over dinner.
Our team at Newpath Partners is guided by a simple ethos - do the right thing and good things will happen.
It's hard to make decisions when you have so much data, so one of the things we were trying to do is actually flesh out the important, significant information so that we can pass it along to leadership so they could make educated decisions.
It takes a long time for scientists to agree on something. You sit there with a big problem, and four people are saying four different things. A year later, 25% of each of us is right, and now we have a completely different proposal.
"Science and medicine were the furthest things removed from everything happening."Tom Cahill — on COVID-19, March 2020